Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial.
Saved in:
| Title: | Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial. |
|---|---|
| Authors: | Reardon, David A.1 (AUTHOR) david_reardon@dfci.harvard.edu, Kim, Tae Min2 (AUTHOR), Frenel, Jean‐Sebastien3 (AUTHOR), Simonelli, Matteo4,5 (AUTHOR), Lopez, Juanita6 (AUTHOR), Subramaniam, Deepa S.7 (AUTHOR), Siu, Lillian L.8 (AUTHOR), Wang, Hui9 (AUTHOR), Krishnan, Suba10 (AUTHOR), Stein, Karen10 (AUTHOR), Massard, Christophe11 (AUTHOR) |
| Source: | Cancer (0008543X). May2021, Vol. 127 Issue 10, p1620-1629. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
